Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Takeda Pharmaceutical Company Limited logo
4502.T
Takeda Pharmaceutical Company Limited
06:30:00
4934 ¥
0.0000 (%0.00)
Previous Close: 5037
Day Low₺4909
Day High₺4970
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

4502.T: Takeda Pharmaceutical Company Limited Financials

Takeda Pharmaceutical Company Limited Income Statement

Total revenue
Net income
Gross margin TTM
51.06%
Operating margin TTM
11.99%
Net profit margin TTM
4.26%
Return on investment TTM
2.47%
Period end31/03/202631/03/202531/03/202431/03/2023
Total revenue4,505,720,000,0004,581,551,000,0004,263,762,000,0004,027,478,000,000
Operating income540,449,000,000627,543,000,000531,423,000,000658,291,000,000
Net income191,762,000,000107,928,000,000144,067,000,000317,017,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Total revenue4,505,720,000,0004,581,551,000,0004,263,762,000,0004,027,478,000,000
Cost of revenue2,205,132,000,0002,126,363,000,0001,938,851,000,0001,729,162,000,000
Gross profit2,300,588,000,0002,455,188,000,0002,324,911,000,0002,298,316,000,000
Research and development expenses675,924,000,000730,226,000,000728,617,000,000633,325,000,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses1,084,215,000,0001,104,732,000,0001,053,819,000,000997,234,000,000
Other expenses0-7,313,000,00011,052,000,0009,466,000,000
Operating expenses1,760,139,000,0001,827,645,000,0001,793,488,000,0001,640,025,000,000
Cost and expenses3,965,271,000,0003,954,008,000,0003,732,339,000,0003,369,187,000,000
Net interest income-146,395,000,000-167,338,000,000-142,338,000,000-130,886,000,000
Interest income211,177,000,00019,638,000,00011,293,000,0005,508,000,000
Interest expense357,572,000,000186,976,000,000153,631,000,000136,394,000,000
Depreciation and amortization721,127,000,000761,396,000,000728,002,000,000664,400,000,000
EBITDA1,338,888,000,0001,127,443,000,000927,954,000,0001,184,514,000,000
EBIT617,761,000,000366,047,000,000199,952,000,000520,114,000,000
Non-operating income (excl. interest)-77,312,000,000261,496,000,000331,471,000,000138,177,000,000
Operating income540,449,000,000627,543,000,000531,423,000,000658,291,000,000
Total other income/expenses (net)-280,260,000,000-452,459,000,000-478,632,000,000-283,201,000,000
Income before tax260,189,000,000175,084,000,00052,791,000,000375,090,000,000
Income tax expense68,163,000,00066,941,000,000-91,406,000,00058,052,000,000
Net income from continuing operations192,026,000,000108,143,000,000144,197,000,000317,038,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income191,762,000,000107,928,000,000144,067,000,000317,017,000,000
Net income deductions0000
Bottom line net income191,762,000,000107,928,000,000144,067,000,000317,017,000,000
EPS1226892204
Diluted EPS1206791202
Weighted average shares outstanding1,575,062,0001,578,873,0001,564,450,0001,551,809,000
Weighted average diluted shares outstanding1,602,783,0001,605,323,0001,580,343,0001,569,872,000

Takeda Pharmaceutical Company Limited Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
4,369,681,000,000%
Total debt / assets MRQ
—
Period end31/03/202631/03/202531/03/202431/03/2023
Total assets15,453,113,000,00014,248,344,000,00015,108,792,000,00013,957,750,000,000
Total liabilities7,678,314,000,0007,312,365,000,0007,834,788,000,0007,603,080,000,000
Total equity7,773,592,000,0006,935,084,000,0007,273,264,000,0006,354,122,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Cash and cash equivalents595,054,000,000233,742,000,000205,190,000,000229,557,000,000
Short-term investments0151,371,000,000252,610,000,000303,973,000,000
Cash and short-term investments595,054,000,000385,113,000,000457,800,000,000533,530,000,000
Net receivables876,348,000,000725,254,000,000697,610,000,000681,693,000,000
Accounts receivable844,312,000,000651,415,000,000612,439,000,000575,431,000,000
Other receivables32,036,000,00073,839,000,00085,171,000,000106,262,000,000
Inventory1,396,620,000,0001,217,349,000,0001,209,869,000,000986,457,000,000
Prepaid expenses0000
Other current assets222,481,000,000193,476,000,000193,301,000,000196,276,000,000
Total current assets3,090,503,000,0002,521,192,000,0002,558,580,000,0002,397,956,000,000
Property, plant and equipment (net)2,120,639,000,0001,968,209,000,0001,989,777,000,0001,691,229,000,000
Goodwill5,809,010,000,0005,324,430,000,0005,410,067,000,0004,790,723,000,000
Intangible assets3,419,348,000,0003,631,560,000,0004,274,682,000,0004,269,657,000,000
Goodwill and intangible assets9,228,358,000,0008,955,990,000,0009,684,749,000,0009,060,380,000,000
Long-term investments448,737,000,000361,926,000,000430,608,000,000378,857,000,000
Tax assets487,867,000,000370,745,000,000393,865,000,000366,003,000,000
Other non-current assets77,009,000,00070,282,000,00051,213,000,00063,325,000,000
Total non-current assets12,362,610,000,00011,727,152,000,00012,550,212,000,00011,559,794,000,000
Other assets0000
Total assets15,453,113,000,00014,248,344,000,00015,108,792,000,00013,957,750,000,000
Total payables589,225,000,000441,947,000,000429,861,000,000539,830,000,000
Accounts payable491,345,000,000308,450,000,000319,955,000,000307,453,000,000
Other payables97,880,000,000133,497,000,000109,906,000,000232,377,000,000
Accrued expenses0000
Short-term debt512,157,000,000613,382,000,000433,459,000,000399,223,000,000
Capital lease obligations (current)0000
Tax payables00109,906,000,000232,377,000,000
Deferred revenue0000
Other current liabilities1,328,148,000,0001,451,192,000,0001,449,783,000,0001,542,887,000,000
Total current liabilities2,429,530,000,0002,506,521,000,0002,313,103,000,0002,481,940,000,000
Long-term debt4,369,681,000,0003,966,326,000,0004,476,501,000,0004,042,741,000,000
Capital lease obligations (non-current)0508,882,000,000553,431,000,000419,728,000,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)26,804,000,00035,153,000,000113,777,000,000270,620,000,000
Other non-current liabilities852,299,000,000295,483,000,000377,976,000,000388,051,000,000
Total non-current liabilities5,248,784,000,0004,805,844,000,0005,521,685,000,0005,121,140,000,000
Other liabilities0000
Capital lease obligations0508,882,000,000553,431,000,000419,728,000,000
Total liabilities7,678,314,000,0007,312,365,000,0007,834,788,000,0007,603,080,000,000
Treasury stock-49,128,000,000-74,815,000,000-51,259,000,000-100,317,000,000
Preferred stock0000
Common stock1,695,277,000,0001,694,685,000,0001,676,596,000,0001,676,345,000,000
Retained earnings1,056,532,000,0001,187,586,000,0001,391,203,000,0001,541,146,000,000
Additional paid-in capital1,776,352,000,0001,775,713,000,0001,747,414,000,0001,728,830,000,000
Accumulated other comprehensive income/loss3,294,559,000,0002,351,916,000,0002,509,310,000,0001,508,119,000,000
Other stockholders' equity0-1,000,0000-1,000,000
Total stockholders' equity7,773,592,000,0006,935,084,000,0007,273,264,000,0006,354,122,000,000
Total equity7,774,800,000,0006,935,979,000,0007,274,005,000,0006,354,671,000,000
Minority interest1,208,000,000895,000,000741,000,000549,000,000
Total liabilities and total equity15,453,113,000,00014,248,344,000,00015,108,793,000,00013,957,751,000,000
Total investments448,737,000,000513,297,000,000683,218,000,000682,830,000,000
Total debt4,881,838,000,0005,088,590,000,0005,463,391,000,0004,861,692,000,000
Net debt4,286,784,000,0004,854,848,000,0005,258,201,000,0004,632,135,000,000

Takeda Pharmaceutical Company Limited Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/03/202631/03/202531/03/202431/03/2023
Cash from operations938,708,000,000962,493,000,000640,321,000,000877,217,000,000
Cash from investing-387,798,000,000-385,355,000,000-488,214,000,000-615,718,000,000
Cash from financing-375,440,000,000-638,441,000,000-254,041,000,000-600,593,000,000
Net change in cash361,312,000,00028,552,000,000-24,367,000,000-620,138,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Net income191,762,000,000107,928,000,000144,067,000,000317,017,000,000
Depreciation and amortization721,127,000,000761,396,000,000728,002,000,000664,400,000,000
Deferred income tax0000
Stock-based compensation0000
Change in working capital-249,921,000,000-69,479,000,000-263,559,000,000-114,042,000,000
Accounts receivable-70,166,000,000-58,959,000,00015,104,000,00075,127,000,000
Inventory-61,293,000,000-34,973,000,000-115,743,000,000-79,155,000,000
Accounts payable-3,150,000,000-7,118,000,000-9,895,000,000-84,804,000,000
Other working capital-115,312,000,00031,571,000,000-153,025,000,000-25,210,000,000
Other non-cash items275,740,000,000162,648,000,00031,811,000,0009,842,000,000
Net cash from operating activities938,708,000,000962,493,000,000640,321,000,000877,217,000,000
Investments in property, plant and equipment-410,933,000,000-347,841,000,000-480,730,000,000-633,689,000,000
Acquisitions (net)39,779,000,00020,634,000,000-4,735,000,0008,920,000,000
Purchases of investments-16,518,000,000-98,540,000,000-6,766,000,000-10,151,000,000
Sales/maturities of investments7,911,000,00087,133,000,0008,021,000,00022,254,000,000
Other investing activities-8,037,000,000-46,741,000,000-4,004,000,000-3,052,000,000
Net cash from investing activities-387,798,000,000-385,355,000,000-488,214,000,000-615,718,000,000
Net debt issuance43,848,000,000-222,260,000,000116,162,000,000-241,670,000,000
Long-term net debt issuance385,628,000,000-249,750,000,000-160,838,000,000-281,670,000,000
Short-term net debt issuance-341,780,000,00027,490,000,000277,000,000,00040,000,000,000
Net stock issuance-51,603,000,000-51,860,000,000-2,326,000,000-26,929,000,000
Net common stock issuance-51,603,000,000-51,860,000,000-2,326,000,000-26,929,000,000
Common stock issuance0000
Common stock repurchased-51,603,000,000-51,860,000,000-2,326,000,000-26,929,000,000
Net preferred stock issuance0000
Net dividends paid-311,901,000,000-302,498,000,000-287,188,000,000-279,416,000,000
Common dividends paid-311,901,000,000-302,498,000,000-287,188,000,000-279,416,000,000
Preferred dividends paid0000
Other financing activities-55,784,000,000-61,823,000,000-80,689,000,000-52,578,000,000
Net cash from financing activities-375,440,000,000-638,441,000,000-254,041,000,000-600,593,000,000
Effect of FX changes on cash185,842,000,00089,855,000,00077,567,000,000-281,044,000,000
Net change in cash361,312,000,00028,552,000,000-24,367,000,000-620,138,000,000
Cash at end of period595,054,000,000233,742,000,000205,190,000,000229,557,000,000
Cash at beginning of period233,742,000,000205,190,000,000229,557,000,000849,695,000,000
Operating cash flow938,708,000,000962,493,000,000640,321,000,000877,217,000,000
Capital expenditure-176,003,000,000-200,795,000,000-175,420,000,000-140,657,000,000
Free cash flow762,705,000,000761,698,000,000464,901,000,000736,560,000,000
Income taxes paid0000
Interest paid0000